Nuveen California Select Tax-Free Income Portfolio
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NXC research report →
Price Chart
About the company
The Nuveen California Select Tax-Free Income Portfolio is a closed-end mutual fund specializing in fixed-income investments. Initially established by Nuveen Investments Inc. , the fund's oversight is a collaborative effort between Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC.
- IPO
- 1992
- HQ
- Chicago, IL, US
Get TickerSpark's AI analysis on NXC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $85.77M
- P/E
- 37.97
- PEG
- -0.30
- P/S
- 23.16
- P/B
- 0.96
- EV/EBITDA
- 25.38
- Div Yield
- 0.65%
- Gross Margin
- 100.00%
- Op Margin
- 90.84%
- Net Margin
- 60.71%
- ROE
- 2.54%
- ROIC
- 3.80%
Latest fiscal year · YoY change
- Revenue
- $3.70M-28.6%
- Gross Profit
- $3.70M-28.6%
- Op Income
- $3.36M
- Net Income
- $2.25M-55.9%
- EPS
- $0.35-56.3%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $13.45
- 52W Low
- $12.41
- 50D MA
- $13.22
- 200D MA
- $12.97
- Beta
- 0.29
- RSI (14)
- 60
- Avg Volume
- 24.35K
No earnings-call transcripts are available for NXC yet.
- Free Float
- 95.0%
- Shares Outstanding
- 6.45M
- Float Shares
- 6.13M
of shares held by institutions
24 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cetera Advisors LLC | 15.00K | ▲ 15.00K |
| Raymond James & Associates | 13.93K | ▲ 60 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 26, 26 | Doshi Parth | other | 0 |
| Oct 16, 25 | Castro Joseph | other | 0 |
| Sep 10, 25 | Page Robert Tanner | other | 0 |
| Dec 2, 24 | Cardella Marc | other | 0 |
| Feb 28, 24 | Ramsay Mary Beth | other | 0 |
| Feb 28, 24 | Nelson James N III | other | 0 |
| Jan 1, 24 | Forrester Michael A | other | 0 |
| Jan 1, 24 | STARR LOREN M | other | 0 |
| Jan 1, 24 | KENNY THOMAS J | other | 0 |
| Jan 1, 24 | Boateng Joseph A | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NXC coverage
Recent articles, reports, and earnings notes.
No research on NXC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NXC report →Immix Biopharma's NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
globenewswire.com · Nov 4
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
marketbeat.com · Oct 4
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
globenewswire.com · Jan 28
Nuveen Select Tax-Free Income Portfolios Announce Completion of Reorganizations
businesswire.com · Jan 12
Nuveen Closed-End Funds Announce Update to Reorganization Distributions
businesswire.com · Dec 30
Nuveen Select Tax-Free Income Portfolios Announce Shareholder Approval of Reorganization
businesswire.com · Dec 18
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
globenewswire.com · Nov 12
Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
globenewswire.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.